Interstitial Lung Disease Life Expectancy

Interstitial Lung Disease Life Expectancy

Not all lung diseases are the same. Each person with a chronic lung disease is unique and the challenges they face are different.

Because of this, doctors and pulmonologist use umbrella terms which better describe certain types of lung disease. Interstitial Lung Disease (ILD) is one of those terms. Interstitial lung disease is a progressive lung condition that makes breathing and physical activity increasingly difficult. Simple tasks such as walking to the mailbox or taking a shower may become extremely time and energy-intensive or, eventually, altogether impossible. As many as 12 million people in America suffer from chronic lung disease, the fourth leading cause of death in the United States, according to Healthline.

About Interstitial Lung Disease

The term interstitial lung disease encompasses over 100 different types of pulmonary disorders that affect the ability of the lungs to absorb oxygen, including a diverse collection of illnesses with a variety of causes, treatments and prognoses. Those who suffer from interstitial lung disease often suffer from an acute and constant shortness of breath that can limit daily activities. Interstitial lung disease is often characterized by scarring of the delicate tissues of the lungs and a subsequent dry, annoying cough.

Interstitial lung disease can develop without apparent cause. Such inexplicable cases are referred to as idiopathic. The most common form of idiopathic interstitial lung disease is pulmonary fibrosis. As interstitial lung disease is a progressive disorder, identifying a known cause for the disease is especially important. Because interstitial lung disease can be caused by environmental factors, removing external triggers may slow the progression of the disease and minimize further damage to the lungs. If the disease is idiopathic, cellular therapy and other forms of regenerative medicine may be beneficial.

Interstitial Lung Disease Life Expectancy

Interstitial Lung Disease Life Expectancy

Unfortunately, due to the progressive nature of interstitial lung disease and the fact there is no known cure, diagnosis can feel like a death sentence. However, exercise, dieting, prescription drugs and cellular therapy can help to slow, or even arrest the disease. Even with all the factors we know about the disease, no current model exists to predict life expectancy for those with the condition.

Treating Advanced Interstitial Lung Disease

Cellular therapy for lung disease has been a growing treatment option over the past few years. At the Lung Institute, a progressive cellular therapy clinic that has emerged as a leader in the global stem cell community, they use cells from the patient’s own body to treat lung disease. The cells are called autologous cells. These cells are taken intravenously from the patient’s blood (venous cells) or bone marrow. The cells are then separated and returned to the body through an intravenous drip. The new healthy cells are attracted to the areas of the damaged lung cells and get to work promoting the healing of lung tissue. This results is the ability of the patients to breathe easier and inevitably get their life back.

A progressive lung disease often leads to a patient needing to take their treatment into their own hands through researching various options that may seem non-traditional. Most patients are not ready to simply give up on their health, and unfortunately, the prognosis that comes along with interstitial lung disease can seem like it’s the only option.

If you or a loved one has emphysema, cellular therapy may be right for you. Contact the Lung Institute for a free consultation or call 888-745-6697.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.